Updated
Alzheimer’s disease: Asian pipelines and global competitors
As of 2026-11-14, Eisai has an approved lecanemab product and an active Phase 2 E2814 trial, while GemVax’s global Phase 2 GV1001 trial is completed. Global comparators include Lilly’s donanemab and Biogen’s investigational tau antisense therapy diranersen. The table separates mechanisms and development status without ranking efficacy across trials.
Focus: disease-modifying therapies. Jurisdictions and trial populations are separated; symptomatic medicines are not exhaustively covered.
Asian companies
| Asset | Company | Mechanism / route | Stage | Indication | Trial ID | Latest verified record | Sources |
|---|---|---|---|---|---|---|---|
lecanemab / LEQEMBI | Eisai / Biogen | Anti-Aβ protofibril antibody IV / SC | Approved; SC pen also approved in Japan | Early Alzheimer’s disease | — | Announced planned five-year follow-up presentations at November CTAD; the conference has not yet occurred. | |
GV1001 | GemVax (South Korea) | Investigational peptide mimicking extra-telomeric hTERT functions SC | Global Phase 2 completed; not approved | Mild-to-moderate Alzheimer’s disease | NCT05189210 is completed. The company webpage still says ongoing; this table uses the registry status. | ||
E2814 | Eisai | Anti-tau antibody with lecanemab IV; with lecanemab | Phase 2; active, not recruiting | Early Alzheimer’s disease | NCT06602258 is active, not recruiting; confirmatory efficacy has not been established. |
Global comparators
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
donanemab / Kisunla | Eli Lilly | Anti-amyloid antibody IV | Approved; indications vary by jurisdiction | Early symptomatic Alzheimer’s disease | Announced diagnostic and therapeutic research at AAIC; this is not a new indication approval. | |
diranersen / BIIB080 | Biogen / Ionis | Antisense oligonucleotide targeting MAPT mRNA Intrathecal | Phase 2 data reported; Phase 3 planned | Early Alzheimer’s disease | Ionis lists Phase 3 initiation of diranersen as an anticipated 2027 milestone in its Q3 update; this remains forward-looking. |
Events in the last 90 days
2026-08-17 – 2026-11-14
diranersen / BIIB080
Ionis lists Phase 3 initiation of diranersen as an anticipated 2027 milestone in its Q3 update; this remains forward-looking. Primary source
lecanemab / LEQEMBI
Announced planned five-year follow-up presentations at November CTAD; the conference has not yet occurred. Primary source
Sources and downloads
- Eisai CTAD announcement — 2026-10-29
- LEQEMBI Pen Japan approval — 2026-09-16
- GV1001 global Phase 2 registry — 2025-09-04
- GemVax expanded access page — Undated
- E2814 Phase 2 registry — 2026-02-11
- E2814 study protocol synopsis — Undated
- Lilly AAIC research announcement — 2026-07-09
- Ionis Q3 update: anticipated milestones — 2026-11-09
- Biogen CELIA data — 2026-07-14
- Biogen CELIA patient disposition and intrathecal dosing — Undated
Information cutoff 2026-11-14